Tata Chemicals · NSE: TATACHEM · BSE: 500770
Q3 FY26 results · Oct–Dec 2025
Tata Chemicals reported revenue from operations of ₹3,550.00 crore (down 1.1% from Q3 FY25) and net loss of ₹69.00 crore for Q3 FY26 (Oct–Dec 2025), on a consolidated basis.
| Item | Q3 FY26 | Q3 FY25 | YoY | Q2 FY26 | QoQ |
|---|---|---|---|---|---|
| Revenue from operations | 3,550.00 | 3,590.00 | −1.1% | 3,877.00 | −8.4% |
| Other income | 38.00 | 28.00 | +35.7% | 138.00 | −72.5% |
| Total income | 3,588.00 | 3,618.00 | −0.8% | 4,015.00 | −10.6% |
| Profit before share of associates & JVs and tax | (110.00) | (36.00) | Loss widened | 181.00 | Turned loss |
| Share of profit/(loss) of associates & JVs | 37.00 | 32.00 | 55.00 | ||
| Net profit for the period | (69.00) | (21.00) | Loss widened | 154.00 | Turned loss |
| Attributable to shareholders of the company | (93.00) | (53.00) | Loss widened | 77.00 | Turned loss |
| EPS, basic (₹) | 3.65 | (2.08) | Turned profit | 3.02 | +20.9% |
| Net margin (%) | -1.9 | -0.6 | 4.0 |
This company reports a share of profit/(loss) from associates and joint ventures. BSE’s filing format records that share after tax, so it is shown on its own line. The company’s own statement may add it before its “profit before tax” line.
| Item | Q3 FY26 | Q3 FY25 | YoY | Q2 FY26 | QoQ |
|---|---|---|---|---|---|
| Revenue from operations | 1,204.00 | 1,166.00 | +3.3% | 1,204.00 | +0.0% |
| Other income | 16.00 | 16.00 | +0.0% | 121.00 | −86.8% |
| Total income | 1,220.00 | 1,182.00 | +3.2% | 1,325.00 | −7.9% |
| Profit before tax | 73.00 | 83.00 | −12.0% | 212.00 | −65.6% |
| Net profit for the period | 73.00 | 72.00 | +1.4% | 178.00 | −59.0% |
| EPS, basic (₹) | 2.87 | 2.83 | +1.4% | 6.99 | −58.9% |
| Net margin (%) | 6.1 | 6.2 | 14.8 |
Consolidated
- Filed with BSE
- 02 Feb 2026, 18:19 IST
- Board meeting
- 02 Feb 2026
- Period
- 01 Oct 2025 to 31 Dec 2025
- Review status
- Unaudited
- Source
- XBRL filing on BSE
Standalone
- Filed with BSE
- 02 Feb 2026, 18:19 IST
- Board meeting
- 02 Feb 2026
- Period
- 01 Oct 2025 to 31 Dec 2025
- Review status
- Audited
- Source
- XBRL filing on BSE